Press
Mammogen Names National Cancer Screening Leader, Dr. Rebecca Kaltman, to Lead Pivotal genTRU-breast™ Study
By IVBH Studio, BioSpace
Mammogen announced the appointment of Rebecca D. Kaltman, M.D., Executive Director of the Inova Saville Cancer Screening and Prevention Center, as Principal Investigator for its KATELYN-ERIN clinical trial.
The study will evaluate genTRU-breast™, Mammogen's RNA-powered blood-based assay being developed to support earlier breast cancer detection, particularly for women with dense breast tissue.
Dr. Kaltman brings 20 years of experience in oncology, cancer prevention, and clinical research. Her leadership marks an important step as Mammogen advances its clinical validation efforts and explores how blood-based diagnostics can complement traditional breast imaging.